Business Context and Reporting Period
Keros Therapeutics, Inc. (KROS) filed a Current Report on Form 8-K on December 12, 2022. The company is a Delaware corporation headquartered in Lexington, Massachusetts, and its common stock trades on The Nasdaq Stock Market LLC. The filing reports on the establishment of a new "at-the-market" (ATM) equity offering program.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on the terms of a new securities offering.
Material Changes
- New ATM Program: The Company filed a prospectus supplement to its existing Shelf Registration Statement to authorize the issuance and sale of up to an additional $250,000,000 of common stock (Placement Shares).
- Exhaustion of Prior Program: The Company has exhausted the $150,000,000 authorized under its previous ATM program established in May 2021.
- Sales Agent: SVB Securities LLC continues to act as the sales agent for the new program.
Guidance, Outlook, and Terms
- Commission: The Company will pay SVB Securities a commission of up to 3.0% of the gross sales proceeds from any Placement Shares sold.
- Sale Method: Shares may be sold directly on or through the Nasdaq Global Market or other existing trading markets, subject to the Company's instructions regarding price or size limits.
- Obligation: The Company is not obligated to sell any shares under the agreement.
- Termination: The offering will terminate upon the sale of all Placement Shares or earlier termination of the agreement.
- Legal Opinion: Cooley LLP issued an opinion regarding the validity of the Placement Shares.
Investor Verification Checklist
- Verify the current share price and potential dilution impact of a $250,000,000 offering.
- Review the Company's cash position and burn rate to assess the necessity of this capital raise.
- Confirm the total number of shares outstanding to calculate the percentage increase in equity if the full $250,000,000 is sold.
- Monitor future 8-K filings for actual sales activity and proceeds generated under this new program.